Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: A retrospective administrative claims analysis

Patient Preference and Adherence

Volumn 5, Issue , 2011, Pages 73-84

  Halpern, Rachel ^a   Agarwal, Sonalee ^b   Dembek, Carole ^b   Borton, Leigh ^a   Lopez Bresnahan, Maria ^c  

^a Health Economics and Outcomes Research   (United States)

^b BIOGEN   (United States)

^c Medical and Scientific Affairs   (United States)

Author keywords

Immunomodulatory therapy; Multiple sclerosis; Patient compliance

Indexed keywords

BETA1A INTERFERON; CORTICOSTEROID; GLATIRAMER; INTERFERON BETA SERINE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT DURATION;

EID: 82455174955     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S15702     Document Type: Article

References (44)

1. Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359(9313): 1221-1231
2. Rolak LA. Multiple sclerosis: it's not the disease you thought it was. Clin Med Res. 2003;1(1):57-60
3. National Multiple Sclerosis Society. Just the facts (2008-2009). Available from: http://www.nationalmssociety.org/about-multiplesclerosis/what-we-know-about-ms/what-is-ms/index.aspx. Accessed Dec 8 2010.
4. Bainbridge JL, Rieckmann P. Multiple sclerosis. In: DiPiro JT, Talbert R, Yee G, Matzke G, editors. Pharmacotherapy: a pathophysiologic approach. New York: McGraw-Hill Medical; 2008. p. 913-926
5. Ropper AH, Samuels MA. Multiple sclerosis and allied demyelinating diseases. Adams and Victor's principles of neurology. 9th ed. New York: McGraw-Hill Medical; 2009:771-796
6. IFNB Multiple Sclerosis Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993;43(4): 655-661
7. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39(3):285-294
8. Johnson KP, Brooks BR, Ford CC, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler. 2000;6(4):255-266
9. PRISMS. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998; 352(9139):1498-1504
10. World Health Organization. Adherence to long-term therapies: Evidence for action. Available from: http://www.who.int/chp/knowledge/publications/adherence_full_report.pdf. Accessed Dec 8 2010.
11. New England Health Care Institute. Thinking outside the pillbox: A system-wide approach to improving patient medication adherence for chronic disease. Available from: http://www.nehi.net/publications/44/thinking_outside_the_pillbox_a_systemwide_approach_to_improving_patient_medication_adherence_for_chronic_disease. Accessed Dec 8 2010.
12. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1): 44-47
13. Steinberg SC, Faris RJ, Chang CF, Chan A, Tankersley MA. Impact of adherence to interferons in the treatment of multiple sclerosis: a nonexperimental, retrospective, cohort study. Clin Drug Investig. 2010; 30(2):89-100
14. Treadaway K, Cutter G, Salter A, et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol. 2009; 256(4):568-576
15. Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2010 Jun 14. [Epub ahead of print].
16. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15(8):565-574
17. Tremlett H, van dM I, Pittas F, et al. Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiol Drug Saf. 2008;17(6): 565-576
18. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA. 2002;288(22):2880-2883
19. Bruce JM, Hancock LM, Lynch SG. Objective adherence monitoring in multiple sclerosis: initial validation and association with self-report. Mult Scler. 2010;16(1):112-120
20. Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology. 2003;61(4):551-554
21. Rio J, Porcel J, Tellez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler. 2005;11(3):306-309
22. Clerico M, Barbero P, Contessa G, Ferrero C, Durelli L. Adherence to interferon-beta treatment and results of therapy switching. J Neurol Sci. 2007;259(1-2):104-108
23. O'Rourke KE, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler. 2005; 11(1):46-50
24. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130-1139
25. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383
26. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619
27. Ollendorf DA, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Managed Care Pharm. 2002;8(6):469-476
28. Reynolds MW, Stephen R, Seaman C, Rajagopalan K. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis. Curr Med Res Opin. 2010;26(3):663-674
29. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care. 2005;11(7): 449-457
30. Abdi H. The Bonferonni and Sidak corrections for multiple comparisons. In: Salkind NJ, editor. Encyclopedia of measurement and statistics. Thousand Oaks, CA: SAGE Publications, Inc; 2007:103-107
31. ®. A practical guide. Cary, NC: SAS Institute, Inc; 1995.
32. Portaccio E, Zipoli V, Siracusa G, Sorbi S, Amato MP. Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. Eur Neurol. 2008;59(3-4):131-135
33. Patti F. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Prefer Adherence. 2010;4:1-9
34. Phillips AL, Ivanova JI, Bergman RE, Birnbaum HG, Stewart M, Meletiche DM. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis. Toronto, Ontario, Canada 2010.
35. Tan H, Yu J, Tabby D, Devries A, Singer J. Clinical and economic impact of a specialty care management program among patients with multiple sclerosis: a cohort study. Mult Scler. 2010;16(8):956-963
36. Girouard N, Theoret G. Management strategies for improving the tolerability of interferons in the treatment of multiple sclerosis. Can J Neurosci Nurs. 2008;30(4):18-25
37. Biogen Idec. Services and support. Avonex patient services. Available from: http://www.avonex.com/service-and-support.xml. Accessed Dec 8 2010.
38. Teva Pharmaceuticals. Shared solutions. Support, knowledge, answers for patients with MS using COPAXONE (glatiramer acetate injection). Available from: http://www.copaxone.com/supportServices/default. aspx. Accessed Dec 8 2010.
39. EMD serono, Inc and Pfizer Inc. MS lifelines. Available from: www. mslifelines.com. Accessed Dec 8 2010.
40. Bayer Healthcare Pharmaceuticals. Betaplus MS support group. Available from: http://www.betaseron.com/patients/betaplus/about_betaplus.jsp. Accessed Dec 8 2010.
41. Smrtka J, Caon C, Saunders C, Becker BL, Baxter N. Enhancing adherence through education. J Neurosci Nurs. 2010;42(5 Suppl):S19-S29.
42. Saunders C, Caon C, Smrtka J, Shoemaker J. Factors that influence adherence and strategies to maintain adherence to injected therapies for patients with multiple sclerosis. J Neurosci Nurs. 2010;42(5 Suppl):S10-S18.
43. Caon C, Saunders C, Smrtka J, Baxter N, Shoemaker J. Injectable disease-modifying therapy for relapsing-remitting multiple sclerosis: a review of adherence data. J Neurosci Nurs. 2010;42(5 Suppl):S5-S9.
44. Caon C, Saunders C, Smrtka J, et al. Introduction: adherence to diseasemodifying therapies-key to optimizing outcomes in relapsing multiple sclerosis. J Neurosci Nurs. 2010;42(5 Suppl):S1-S4.